Reproductive health, biosimilars, IgG4-related disease and much more—five speakers give us a sneak peek into important topics being addressed at the ACR’s 2025 State-of-the-Art Clinical Symposium, April 4–6.
Lupus: Closer to a Cause?
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
Neuropsychiatric Lupus Research Benefits from Functional MRI & Insights into Microglia
Experts described the latest breakthroughs related to lupus and the brain, including the use of functional magnetic resonance imaging (fMRI) to gain insights into brain fog. Research into the role of microglia in neuropsychiatric lupus is also described.
Break the Barrier: Understanding & Treating Neuropsychiatric Lupus
Updated research on the complexities of central nervous system (CNS) lupus, as well as its diagnosis and treatment are discussed.
2 AC&R Study Summaries: Racial Disparities in Lupus Trials & Post-Discharge Follow-Up in Lupus
Racial Disparities in Lupus Clinical Trial Participation By Saira Z. Sheikh, MD Why was this study done? Lupus disproportionately affects Black and Latino populations, particularly women in childbearing years. Clinical trials of patients with lupus can advance the development of therapeutics and access to better treatments, as well as improve health outcomes for patients. However,…
The Complexity of SLE Drug Research
PHILADELPHIA—On Saturday, Nov. 12, at ACR Convergence 2022, Joan T. Merrill, MD, director of clinical projects in the Arthritis & Clinical Immunology Program at the Oklahoma Medical Research Foundation in Oklahoma City, gave a presentation on the future of drug development and treatments for systemic lupus erythematosus (SLE). She described how an in-depth understanding of…
Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022
PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
Rare Disease Sheds Light on the Origins of Lupus
Patients with the rare DNASE1L3 biallelic null mutation present with childhood-onset disease that resembles lupus. This observation prompted research into how abnormalities in the enzyme DNASE1L3 are associated with lupus, with researchers finding autoantibody-mediated impairment of DNASE1L3 activity may be a common non-genetic mechanism leads to anti-dsDNA autoreactivity in SLE.
Lupus or Not? Machine Learning May Help Diagnose Lupus Early
Can machine learning aid clinicians in diagnosing systemic lupus erythematosus? Adamichou et al. designed an algorithm that uses classical features of lupus to simulate medical reasoning and identify lupus early in the disease process. They were able to validate the algorithm, which demonstrated high sensitivity, specificity and accuracy.
A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
- 1
- 2
- 3
- …
- 18
- Next Page »